Axel Heidenreich
Overview
Explore the profile of Axel Heidenreich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
459
Citations
9418
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Heidenreich A, Bohmer D, Bolenz C, Borkowetz A, Rieger C, De Santis M
Dtsch Arztebl Int
. 2025 Feb;
(Forthcoming).
PMID: 39964043
Background: 17 500 persons receive a new diagnosis of urothelial carcinoma of the bladder in Germany each year. Radical cystectomy is performed for muscle-invasive and for non-muscle-invasive, recurrent, high-risk tumors....
3.
Perrone E, Giordano A, Calcagni M, Leccisotti L, Moretti R, Eismant A, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941774
This study aims to retrospectively assess the safety of [Ac]Ac-PSMA-PRLT, both as monotherapy and in combination (TANDEM) with Lutetium-177, concerning tolerance after the radiopharmaceutical administration and long-term safety, its impact...
4.
Patrikidou A, Oing C, Markellos C, Heidenreich A, Leao R, Nicolai N, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39915218
The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above...
5.
Steenbock O, Paffenholz P, Rieger C, Heidenreich J, Pfister D, von Brandenstein M, et al.
Urologie
. 2025 Jan;
64(3):256-268.
PMID: 39836208
Introduction: Prostate cancer guidelines recommend molecular analysis of biomaterial following resistance to first-line systemic therapy in order to identify druggable mutations. We report on our results of molecular analysis of...
6.
Heidenreich A, Albers P, Michel M
Urologie
. 2025 Jan;
64(1):1-3.
PMID: 39808293
No abstract available.
7.
Muhler P, Akuamoa-Boateng D, Rosenbrock J, Stock S, Muller D, Heidenreich A, et al.
BMJ Open
. 2025 Jan;
15(1):e088495.
PMID: 39800402
Background: Magnetic resonance-guided transurethral ultrasound ablation (MR-TULSA) is a new focal therapy for treating localised prostate cancer that is associated with fewer adverse effects (AEs) compared with established treatments. To...
8.
Antonelli L, Heidenreich A, Bagrodia A, Amini A, Baky F, Branger N, et al.
BJU Int
. 2024 Dec;
PMID: 39662898
Objectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients...
9.
10.
Giannini G, Kafka M, Neuwirt H, Artamonova N, di Santo G, Virgolini I, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102260.
PMID: 39608079
Background: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited. Methods:...